Associate Professor of Oncology, Johns Hopkins University School of Medicine
Hematology
Dr. Noah M. Hahn, MD
|
|
Give Review
Doctor Noah M. Hahn, MD is an expert in the field of Hematology. He attended Indiana University School of Medicine. Indiana University School of Medicine is ranked 45/47 in Research/PrimaryCare. He over the years received 1 awards: "CMS Meaningful Use Stage 1 Certification". Noah Hahn has written publications. He has 47 publications published with PubMed. The lastest paper is: 'New Strategies in Bladder Cancer: A Second Coming for Immunotherapy.' Noah Hahn is registered with Medicare.
Publications
- New Strategies in Bladder Cancer: A Second Coming for Immunotherapy.
- Immune checkpoint inhibitors: a new frontier in bladder Cancer.
- Involvement of Epigenetics and EMT-Related miRNA in Arsenic-Induced Neoplastic Transformation and Their Potential Clinical Use.
- Quantification of 5-methylcytosine, 5-hydroxymethylcytosine and 5-carboxylcytosine from the blood of Cancer patients by an enzyme-based immunoassay.
- A National Multicenter Phase 2 Study of Prostate-specific Antigen (PSA) Pox Virus Vaccine with Sequential Androgen Ablation Therapy in Patients with PSA Progression: E...
- Plasmacytoid variant urothelial bladder Cancer: Is it time to update the treatment paradigm?
- Heat shock and other apoptosis-related proteins as therapeutic targets in prostate Cancer.
- Novel bone-targeting agents in prostate Cancer.
- Failure to Suppress Markers of Bone Turnover on First-Line Hormone Therapy for Metastatic Prostate Cancer Is Associated With Shorter Time to Skeletal-Related Event.
- Posttreatment prognostic nomogram for patients with metastatic urothelial Cancer completing first-line cisplatin-based chemotherapy.
- Nomogram for predicting survival in patients with unresectable and/or metastatic urothelial Cancer who are treated with cisplatin-based chemotherapy.
- Relationship between 6- and 9-month progression-free survival and overall survival in patients with metastatic urothelial Cancer treated with first-line cisplatin-base...
- EGFR alterations and EML4-ALK rearrangement in primary adenoCarcinoma of the urinary bladder.
- Novel markers of squamous differentiation in the urinary Bladder.
- The Impact of Gender on Outcomes in Patients With Metastatic Urothelial Carcinoma.
- Elevated phospholipase A2 activities in plasma samples from multiple Cancers.
- Critical analysis of contemporary clinical research in muscle-invasive and metastatic urothelial Cancer: a report from the Bladder Cancer Advocacy Network Clinical Tri...
- Cisplatin-based combination chemotherapy in septuagenarians with metastatic urothelial Cancer.
- Risk of venous thromboembolism in patients with Cancer treated with Cisplatin: a systematic review and meta-analysis.
- DNMT1: An emerging target in the treatment of invasive urinary bladder Cancer.
- Sipuleucel-T (Provenge) autologous vaccine approved for treatment of men with asymptomatic or minimally symptomatic castrate-resistant metastatic prostate Cancer.
- Subcutaneous 5-azacitidine treatment of naturally occurring canine urothelial Carcinoma: a novel epigenetic approach to human urothelial Carcinoma drug development.
- Double-Blind, Randomized Trial of Docetaxel Plus Vandetanib Versus Docetaxel Plus Placebo in Platinum-Pretreated Metastatic Urothelial Cancer.
- Successful recruitment of healthy African American men to genomic studies from high-volume community health fairs: Implications for future genomic research in minority...
- Treatment of patients with metastatic urothelial Cancer "unfit" for Cisplatin-based chemotherapy.
- Phase II Trial of Cisplatin, Gemcitabine, and Bevacizumab As First-Line Therapy for Metastatic Urothelial Carcinoma: Hoosier Oncology Group GU 04-75.
- ACR appropriateness criteria postradical prostatectomy irradiation in prostate Cancer.
- Ionizing radiation induces neuroendocrine differentiation of prostate Cancer cells in vitro, in vivo and in prostate Cancer patients.
- A phase II study of 2-methoxyestradiol (2ME2) NanoCrystal® dispersion (NCD) in patients with taxane-refractory, metastatic castrate-resistant prostate Cancer (CRPC).
- Suggestions for regulatory agency approval of second-line systemic therapy for metastatic transitional Cell carcinoma.
- Learning to control cyclophosphamide induced cystitis.
- Patient with Malignant paraganglioma responding to the multikinase inhibitor sunitinib malate.
- Hoosier Oncology Group randomized phase II study of docetaxel, vinorelbine, and estramustine in combination in hormone-refractory prostate Cancer with pharmacogenetic ...
- Germ Cell tumors: an update of recent data and review of active protocols in stage I and metastatic disease.
- Does linezolid cause lactic acidosis by inhibiting mitochondrial protein synthesis?
- Combined chemoradiotherapy in small cell lung Cancer.
- Presence of the metabolic syndrome is associated with shorter time to castration-resistant prostate Cancer.
- A phase II study of pemetrexed as second-line chemotherapy for the treatment of metastatic castrate-resistant prostate Cancer (CRPC); Hoosier Oncology Group GU03-67.
- Novel agents for muscle-invasive and advanced urothelial Cancer.
- Neoadjuvant therapy followed by prostatectomy for clinically localized prostate Cancer.
- Second-line systemic therapy and emerging drugs for metastatic transitional-Cell carcinoma of the urothelium.
- Hypomethylating agents for urologic Cancers.
- A consensus definition of patients with metastatic urothelial Carcinoma who are unfit for cisplatin-based chemotherapy.
- Epigenetics in prostate Cancer.
- Constitutional polymorphisms of prostate Cancer: prognostic and diagnostic implications.
- American College of Radiology Appropriateness Criteria permanent source brachytherapy for prostate Cancer.
Schools
Indiana University School Of Medicine
Emory University Hospital
Duke University
Indiana University
Procedures Preformed
- Thoracentesis
Conditions Treated
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- Basal Cell Carcinoma
- View All
Doctors Specialties
- Medical Oncology
- Oncology
- Hematology
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
Education
-
Indiana University School of Medicine -
Duke University Hospital -
Emory University
Hospital
-
Johns Hopkins Hospital -
Johns Hopkins Bayview Medical Center
Drug Facts
| NPI NUMBER | 1376582197 | |
| NPPES Provider LastName | HAHN | |
| NPPES Provider FirstName | NOAH | |
| NPPES Provider ZIPCode | 462025112 | |
| NPPES Provider State | IN | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 1160.0 | |
| Distinct Opioid Count | 4.0 | |
| Opioid Claim Count | 175.0 | |
| Percent Opioid Claims | 15.09 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1376582197 |
| Last Name Of The Provider | HAHN |
| First Name Of The Provider | NOAH |
| View All |
Similar Doctors
|
|
Dr. Rakesh P. Mehta, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Scott B. Saxman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Patrick J. Loehrer Sr., MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Shadia I. Jalal, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Matthew D. Carr, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Shivaji R. Gunale, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Daniel A. Rushing, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Subhash C. Sharma, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David B. Wilson, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Heiko Konig, MD |